TITLE

Single-Dose Fluconazole versus Standard 2-Week Therapy for Oropharyngeal Candidiasis in HIV-Infected Patients: A Randomized, Double-Blind, Double-Dummy Trial

AUTHOR(S)
Hamza, Omar J. M.; Matee, Mecky I. N.; Brüggemann, Roger J. M.; Moshi, Mainen J.; Simon, Elison N. M.; Mugusi, Ferdinand; Mikx, Frans H. M.; van der Lee, Henrich A. L.; Verweij, Paul E.; van der Ven, André J. A. M.
PUB. DATE
November 2008
SOURCE
Clinical Infectious Diseases;11/15/2008, Vol. 47 Issue 10, p1270
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Oropharyngeal candidiasis is the most common opportunistic infection affecting patients with human immunodeficiency virus (HIV) infection. Because of convenience, cost, and reluctance to complicate antiretroviral treatment regimens, single-dose fluconazole may be a favorable regimen for treatment of moderate to severe oropharyngeal candidiasis. We conducted a prospective, randomized, double-blind, placebo-controlled trial to compare the clinical and mycological responses, relapse rates, and safety of a single 750-mg dose and a 14-day course of treatment with fluconazole. Methods. A total of 220 HIV-infected patients with clinical and mycological evidence of oropharyngeal candidiasis were randomly assigned in a 1:1 ratio to receive either a 750-mg single dose of orally administered fluconazole (110 patients) or 150 mg of orally administered fluconazole once per day for 2 weeks (110 patients). The primary efficacy analysis was based on clinical and mycological responses at the end of treatment. Secondary parameters were safety and relapse rate. Results. Single-dose fluconazole was equivalent to a 14-day course of fluconazole in achieving clinical and mycological cure, with clinical cure rates of 94.5% and 95.5%, respectively (odds ratio, 0.825; 95% confidence interval, 0.244-2.789; P = .99), and mycological cure rates of 84.5% and 75.5%, respectively (odds ratio, 1.780; 95% confidence interval, 0.906-3.496; P = .129). Drug-related adverse events were uncommon and were not different between the treatment groups. Conclusion. A single dose of 750 mg of fluconazole was safe, well tolerated, and as effective as the standard 14-day fluconazole therapy in patients with HIV infection and acquired immunodeficiency syndrome who had oropharyngeal candidiasis coinfection. Trial registration. ClinicalTrials.gov identifier: NCT00553137.
ACCESSION #
34948603

 

Related Articles

  • Long-Term Remission in Progressive Multifocal Leukoencephalopathy Caused by Idiopathic CD4+ T Lymphocytopenia: A Case Report. Rueger, M. A.; Miletic, H.; Dorries, K.; Wyen, C.; Eggers, C.; Deckert, M.; Faetkenheuer, G.; Jacobs, A. H. // Clinical Infectious Diseases;4/1/2006, Vol. 42 Issue 7, pE53 

    Progressive multifocal leukoencephalopathy is caused by JC virus, an opportunistic infection of the central nervous system. Antiretroviral treatment for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients is beneficial, but few data exist for patients who...

  • When and why to start antiretroviral therapy? Gatell, Jose M. // Journal of Antimicrobial Chemotherapy (JAC);Mar2010, Vol. 65 Issue 3, p383 

    The question about when to start antiretroviral therapy in HIV-1-infected patients has been debated since the discovery of the first antiretroviral agent (zidovudine) back in 1986 and has been fuelled by the introduction of highly active combined antiretroviral therapy (cART) 10 years later in...

  • Life Stress and Adherence to Antiretroviral Therapy among HIV-Positive Individuals: A Preliminary Investigation. Bottonari, Kathryn A.; Roberts, John E.; Ciesla, Jeffrey A.; Hewitt, Ross G. // AIDS Patient Care & STDs;Nov2005, Vol. 19 Issue 11, p719 

    The present study sought to investigate the impact of life stress on treatment adherence and viral load of HIV-positive individuals. Three different aspects of life stress were examined in this investigation (perceived stress, acute life events unrelated to the HIV illness, and HIVrelated acute...

  • Antiretroviral Therapy Is Associated with Reduced Serologic Failure Rates for Syphilis among HIV-Infected Patients. Ghanem, Khalil G.; Moore, Richard D.; Rompalo, Anne M.; Erbelding, Emily J.; Zenilman, Jonathan M.; Gebo, Kelly A. // Clinical Infectious Diseases;7/15/2008, Vol. 47 Issue 2, p258 

    Background. Syphilis and human immunodeficiency virus (HIV) frequently coexist in patients, but the effects of immunosuppression on the course of syphilis are unknown. Our goal was to determine whether the degree of HIV-mediated immunosuppression and the use of highly active antiretroviral...

  • Uptake of HIV testing and treatment in an isolated population with access to free and universal healthcare. Gillieatt, Sue J.; Mallal, Simon A.; Gillieatt, S J; Mallal, S A // International Journal of STD & AIDS;May2000, Vol. 11 Issue 5, p303 

    This Western Australian study analysed clinical information from 344 people with AIDS, and experiential data from a sample of 36 people with AIDS to investigate 2 relevant issues: the timing of HIV testing and uptake and experiences of HIV drug treatment. We found that the proportion of people...

  • Viral Pathogens Including Human Metapneumovirus Are the Primary Cause of Febrile Respiratory Illness in HIV-Infected Adults Receiving Antiretroviral Therapy. Klein, Marina B.; Hong Yang; DelBalso, Lina; Carbonneau, Julie; Frost, Eric; Boivin, Guy // Journal of Infectious Diseases;1/15/2010, Vol. 201 Issue 2, p297 

    To determine the spectrum of pathogens causing acute febrile respiratory illness in human immunodeficiency virus (HIV)- infected adults, we re-analyzed data from a prospective surveillance study involving 50 outpatients (90% of whom received highly active antiretroviral therapy). Nasopharyngeal...

  • Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel. Hirsch, Martin S.; Günthard, Huldrych F.; Schapiro, Jonathan M.; Brun-Vézinet, Françoise; Clotet, Bonaventura; Hammer, Scott M.; Johnson, Victoria A.; Kuritzkes, Daniel R.; Mellors, John W.; Pillay, Deenan; Yeni, Patrick G.; Jacobsen, Donna M.; Richman, Douglas D. // Clinical Infectious Diseases;7/15/2008, Vol. 47 Issue 2, p266 

    Resistance to antiretroviral drugs remains an important limitation to successful human immunodeficiency virus type 1 (HIV-1) therapy. Resistance testing can improve treatment outcomes for infected individuals. The availability of new drugs from various classes, standardization of resistance...

  • Review: Does HIV Infection Alter the Incidence or Pathology of Helicobacter pylori Infection? Romanelli, Frank; Smith, Kelly M.; Murphy, Brian S. // AIDS Patient Care & STDs;Dec2007, Vol. 21 Issue 12, p908 

    Gastrointestinal (GI) discomfort is a common complaint among patients infected with HIV. GI symptoms can be caused by a myriad of factors including but not limited to coinfections, antiretroviral therapy, medications for opportunistic infections, and nutritional status. Some researchers have...

  • HAART-related nephropathies in HIV-infected patients. Daugas, Eric; Rougier, Jean-Philippe; Hill, Gary // Kidney International;Feb2005, Vol. 67 Issue 2, p393 

    HAART-related nephropathies in HIV-infected patients. There is no doubt that highly active antiretroviral therapy (HAART) has been the most important progress in the therapy of human immunodeficiency virus (HIV)-infected patients in the last decade. A growing number of observations suggest that...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics